

Date and Time:	4th July 2012; 10.30 – 16.30hrs
-----------------------	---

Minutes:		
Guideline Development Group Meeting		
Place:	<i>Boardroom, Level 5, 180 Great Portland Street, London, W1W 5QZ</i>	
Present:	<p>Philip Conaghan (Chair) Mark Porcheret (MP) Elspeth Wise (EW) Ian Bernstein (IB) Fraser Birrell (FB) Michael Doherty (MD) Peter Kay (PK) Rob Middleton (RM) Brian Lucas (BL) Krysia Dziedzic (KD) Weiya Zhang (WZ) Erika Baker (EB) Richard Frearson (RF) Tony Whiting (TW) Jo Cumming (JC)</p> <p>Smita Padhi, Research Fellow (SP) Vanessa Delgado Nunes, Guideline Lead and Senior Research Fellow (VDN) Margaret Constanti, Health Economist (MC) Sue Latchem, Guideline Lead and Operations Director (SL) Paul Miller, Information Scientist (PM)</p> <p>Claire Turner, Guidelines Commissioning Manager, NICE</p>	
Co-opted experts		
None for this meeting		
Apologies:		
Sara Buckner, Research Fellow		
Observers:		
None for this meeting		
Declarations of Interest		
PC		

Declared a personal pecuniary interest:

Attended an advisory board of company who want to market a topical OA product called FLEXISEQ funded by Bollin Strategies for Pro Bono Bio UK. It will need to undergo Technology Appraisal, likely to be in late 2013 so will not be related to the development timeframe of the guideline.

MD

Declared a non-personal non-specific pecuniary interest:

Approached by a company called Ariel Pharmaceuticals who have a new analgesic compound that promises to show good efficacy and safety. Theoretically it should have no side-effects on the bowel, kidney or blood pressure. They have data in headache that shows good efficacy compared to oral NSAID. They have no data on OA but now want to do an RCT in OA and are keen to discuss Nottingham as the lead centre. If he took it on he would wish to compare the drug against both NSAID and paracetamol. The drug is not available commercially. He is keen to explore this further on behalf of Arthritis Research UK Pain Centre and possibly work towards an integrated programme of research on this novel compound that additionally includes animal models and focused human safety studies. This interest would not clash with the guideline timings.

Declared personal specific non pecuniary interests:

He attended the EULAR Congress in Berlin - no honorarium but his expenses were paid for by EULAR.

The EULAR Textbook of Rheumatology was launched in Berlin – He is a co-editor and wrote the chapter on "Management of OA". He will receive an honorarium for being a co-editor (unsure how much as yet)

KD

Declared personal non-pecuniary interests:

Delivered two presentations at EULAR Berlin 2012 5-9th June:

- An overview of best practices in OA care
- Self management of OA in primary care: the role of the multidisciplinary team.

Both referred to CG59. The co-editor of a book on evidence based Rheumatology for Physiotherapists and Occupational Therapists was at the conference. Travel and accommodation as invited speaker and accommodation of accompanying person paid by EULAR.

WZ

Declared a non-personal non-specific pecuniary interest:

Approached by a company called Ariel Pharmaceuticals who have a new analgesic compound that promises to show good efficacy and safety. Theoretically it should have no side-effects on the bowel, kidney or blood pressure. They have data in headache that shows good efficacy compared to oral NSAID. They have no data on OA but now want to do an RCT in OA and are keen to discuss Nottingham as the lead centre, and Weiya would be involved in developing the OA trial design.

FB

Declared personal non pecuniary interests
Sponsorship to attend EULAR Berlin 2012 Servier (oral presentation)
Regional Advisory Board Servier 13/3/12
Medical Liaison Training Servier 16/3/12
National Advisory Board Servier (Chair) 8/6/12
National Advisory Board- Servier Ireland (Chair) 12/9/12
Article for Servier Medicographia journal 1/9/12

All honoraria have been put into research accounts

Co-author on the Atchia 2011 paper discussed as part of the evidence review. The chair deemed no action necessary.

MP

Declared a personal non pecuniary interest:

Speaking at a House of Commons meeting organised by Arthritis research UK to raise MPs' awareness of OA and other musculoskeletal problems, and speaking on "What musculoskeletal problems an average GP sees".

1. Philip Conaghan welcomed the group to the fourth meeting of this GDG. Philip Conaghan asked the GDG for any new DOIs since GDG meeting 1.
2. Smita Padhi and Margaret Constanti presented the clinical and cost effectiveness evidence related to the use of hyaluronan injections in the management of OA.
3. Vanessa Delgado Nunes facilitated the session on decision-making and agreement of any draft recommendations on the use of hyaluronan injections in the management of OA.
4. The GDG revisited the linking evidence to recommendations section drafted for both the nutraceuticals and acupuncture evidence reviews.
5. Vanessa Delgado Nunes presented the evidence review protocol on the efficacy and safety of the use of paracetamol in the management of OA and the GDG was informed that the evidence review would be delivered at GDG meeting 5 on the 25th September.
6. Margaret Constanti presented the health economics priorities in terms of modelling work for the guideline update.
7. Vanessa Delgado Nunes facilitated discussion with the GDG in refining the clinical question related to referral to surgery in OA.
8. Philip Conaghan asked the GDG whether there were any items under AOB and closed the meeting at 16.50hrs.

Date, time and venue of the next meeting

25th September 2012, 10:30 – 16:30hrs.

